Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaozhenzhiyang decoction is a Traditional Chinese Medicine (TCM) herbal formula developed for the topical treatment of skin toxicities, specifically facial rash, induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in cancer patients. The formula is designed to clear heat, detoxify, and relieve itching, addressing the inflammatory skin reactions common with EGFR inhibitors such as osimertinib, gefitinib, or erlotinib. It is typically applied externally as a wash or wet compress. The decoction has been evaluated in clinical trials led by The First Affiliated Hospital of Guangzhou University of Chinese Medicine to assess its efficacy and safety as a supportive care intervention for oncology patients experiencing drug-induced eruptions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaozhenzhiyang decoction.